N@N

Market Maker Surveillance Report. AEZS, NATR, KERX, BCRX, SNSS, SCEI, Winning Stocks With Lowest Price Friction For Monday, Ma

March 5, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3570 companies with "abnormal" market making, 2317 companies with positive Friction Factors and 3755 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. AETERNA ZENTARIS INC (NASDAQ:AEZS), NATURES SUNSHINE PRODS INC (NASDAQ:NATR), KERYX BIOPHARMACEUTICALS (NASDAQ:KERX), BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX), SUNESIS PHARMACEUTICALS INC (NASDAQ:SNSS), SINO CLEAN ENERGY INC (OTC:SCEI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     AEZS       $0.380       21.71%       7,803,222       52.31%       7,099,223       47.59%       703,999         18,526  
     NATR       $2.310       15.79%       65,110          49.91%       61,537          47.18%       3,573           15      
     KERX       $1.250       33.78%       15,377,127      51.87%       14,012,415      47.27%       1,364,712       10,918  
     BCRX       $1.010       21.54%       1,283,094       57.35%       951,542         42.53%       331,552         3,283   
     SNSS       $0.310       17.92%       298,821         53.84%       256,231         46.16%       42,590          1,374   
     SCEI       $0.620       22.46%       2,486,722       50.07%       2,468,527       49.70%       18,195          293     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows AEZS with a dollar gain Monday of $0.38000 and a Friction Factor of 18,526 shares. That means that it only took 18,526 more shares of buying than selling to move AEZS higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

AETERNA ZENTARIS INC (NASDAQ:AEZS) - terna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrinology. Its lead oncology compounds include perifosine, an orally active PI3K/Akt pathway inhibitor that is in Phase III registration trial for multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of advanced ovarian and endometrial cancer. The companys lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for Adult Growth Hormone Deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.

NATURES SUNSHINE PRODS INC (NASDAQ:NATR) - Natures Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide. The company offers herbal products in the form of capsules or tablets; single herbs and herb combinations in the form of liquid herbs and extracts; vitamins and mineral supplements in the form of chewable or non-chewable tablets; personal care products, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser; and various other products, such as nutritional drinks, homeopathic products, and powders. It sells its products to a sales force of independent distributors and managers, who use the products themselves or resell them to other distributors or consumers. The company also exports its products to various countries, including Argentina, Australia, Chile, New Zealand, and Norway. Natures Sunshine Products, Inc. was founded in 1972 and is based in Provo, Utah.

KERYX BIOPHARMACEUTICALS (NASDAQ:KERX) - Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. The companys products under development include KRX-0401 (perifosine), a phase III clinical stage product, which is an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival; and Zerenex (ferric citrate), an oral iron-based compound, which completed phase II clinical stage for the treatment of hyperphosphatemia in patients with end-stage renal disease. It has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York.

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS). Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX-4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Durham, North Carolina.

SUNESIS PHARMACEUTICALS INC (NASDAQ:SNSS) - Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in platinum-resistant ovarian cancer patients. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of Raf kinase and up to five additional targets that play a role in oncology and immunology indications. The company, formerly known as Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.

SINO CLEAN ENERGY INC (OTC:SCEI) - Sino Clean Energy Inc., through its subsidiaries, operates as a third party commercial producer and distributor of coal-water slurry fuel (CWSF) in the Peoples Republic of China. The companys CWSF products are primarily used in boilers and furnaces to generate steam and heat for residential and industrial applications. It sells its products directly to various customers, including industrial, commercial, residential, and government organizations. The company is headquartered in Xian, the People's Republic of China.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net